{"id":"NCT00289874","sponsor":"Organon and Co","briefTitle":"Montelukast in Pediatric Allergic Asthma (0476-336)(COMPLETED)","officialTitle":"A Multicenter, Double-Blind, Placebo Controlled, Randomized, Parallel-Group Study to Evaluate the Clinical Effect of Oral Montelukast Versus Placebo in Persistent Asthma Which is Also Active During Allergy Seasons in Pediatric Patients With Seasonal Aeroallergen Sensitivity","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-03","primaryCompletion":"2007-07","completion":"2007-07","firstPosted":"2006-02-10","resultsPosted":"2010-10-01","lastUpdate":"2022-02-02"},"enrollment":421,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"montelukast sodium","otherNames":["MK0476"]},{"type":"DRUG","name":"Comparator: Placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"This is a 3-week study to evaluate FEV1 following treatment with drugs in persistent asthma which is also active during allergy seasons in pediatric patients with seasonal aeroallergen sensitivity.","primaryOutcome":{"measure":"Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 3","timeFrame":"Baseline and week 3","effectByArm":[{"arm":"Montelukast 5 mg","deltaMin":9.53,"sd":null},{"arm":"Placebo","deltaMin":9.15,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":1},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["19484680"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":203},"commonTop":[]}}